(19)
(11) EP 1 543 327 A2

(12)

(88) Date of publication A3:
21.10.2004

(43) Date of publication:
22.06.2005 Bulletin 2005/25

(21) Application number: 03788590.2

(22) Date of filing: 15.08.2003
(51) International Patent Classification (IPC)7: G01N 33/53, C12N 15/09, C12N 9/99
(86) International application number:
PCT/US2003/025766
(87) International publication number:
WO 2004/016223 (26.02.2004 Gazette 2004/09)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 16.08.2002 US 404008 P
16.12.2002 GB 0229244

(71) Applicant: Aventis Pharmaceuticals, Inc.
Bridgwater, New Jersey 08807-2854 (US)

(72) Inventors:
  • LI, Zhuyin
    Flemington, NJ 08822 (US)
  • XIONG, Junjie
    Raritan, NJ 08869 (US)
  • MA, Y., Henry DI
    DECEASED (US)
  • SABOL, Jeffrey, S.
    Bridgewater, NJ 08807 (US)

(74) Representative: Löwrick, Oliver, Dr. 
Aventis Pharma Deutschland GmbH,Patent- und Lizenzabteilung
65926 Frankfurt am Main
65926 Frankfurt am Main (DE)

   


(54) METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DECREASE THE ACTIVITY OF MICROSOMAL PROSTAGLANDIN E SYNTHASE OR HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE